| For: | Pejnovic N, Jeftic I, Jovicic N, Arsenijevic N, Lukic ML. Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis. World J Gastroenterol 2016; 22(44): 9706-9717 [PMID: 27956794 DOI: 10.3748/wjg.v22.i44.9706] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v22/i44/9706.htm |
| Number | Citing Articles |
| 1 |
Hee-Won Moon, Mikyoung Park, Mina Hur, Hanah Kim, Won Hyeok Choe, Yeo-Min Yun. Usefulness of Enhanced Liver Fibrosis, Glycosylation Isomer of Mac-2 Binding Protein, Galectin-3, and Soluble Suppression of Tumorigenicity 2 for Assessing Liver Fibrosis in Chronic Liver Diseases. Annals of Laboratory Medicine 2018; 38(4) doi: 10.3343/alm.2018.38.4.331
|
| 2 |
Liang Chen, Chun Hu, Molly Hood, Juntao Kan, Xiaona Gan, Xue Zhang, Yi Zhang, Jun Du. An Integrated Approach Exploring the Synergistic Mechanism of Herbal Pairs in a Botanical Dietary Supplement: A Case Study of a Liver Protection Health Food. International Journal of Genomics 2020; 2020 doi: 10.1155/2020/9054192
|
| 3 |
Kyung Eun Kim, Hyun Joo Shin, Yeajin Ju, Youngae Jung, Hyeong Seok An, So Jeong Lee, Eun Ae Jeong, Jaewoong Lee, Geum-Sook Hwang, Gu Seob Roh. Intermittent Fasting Attenuates Metabolic-Dysfunction-Associated Steatohepatitis by Enhancing the Hepatic Autophagy–Lysosome Pathway. Nutrients 2023; 15(21) doi: 10.3390/nu15214574
|
| 4 |
Melisa Kozaczek, Walter Bottje, Elizabeth Greene, Kentu Lassiter, Byungwhi Kong, Sami Dridi, Soheila Korourian, Reza Hakkak. Comparison of liver gene expression by RNAseq and PCR analysis after 8 weeks of feeding soy protein isolate- or casein-based diets in an obese liver steatosis rat model. Food & Function 2019; 10(12) doi: 10.1039/C9FO01387C
|
| 5 |
Evgenija Homsak, Damien Gruson. Soluble ST2: A complex and diverse role in several diseases. Clinica Chimica Acta 2020; 507 doi: 10.1016/j.cca.2020.04.011
|
| 6 |
Ming-Shyan Lin, Ya-Chi Tu, Yu-Sheng Lin, Meng-Hung Lin, Chun-Liang Lin, Ming-Horng Tsai, Yung-Yu Hsieh, Tien-Hsing Chen, Mei-Yen Chen, Chung-Sheng Shi. Association between galectin-3 and hepatosteatosis in a community-based cross-sectional study. Therapeutic Advances in Chronic Disease 2024; 15 doi: 10.1177/20406223241302719
|
| 7 |
Vesna Brzački, Andriana Jovanović, Andrija Rančić, Snežana Tešić-Rajković, Gordana Petrović, Ivan Nagorni, Marko Stojanović, Elena Stanković, Stefan Momčilović. Circulating and Tissue Galectin-3 in Gastrointestinal Inflammation: Clinical Significance and Biomarker Potential. Cells 2025; 14(19) doi: 10.3390/cells14191521
|
| 8 |
Qian Jiang, Qijin Zhao, Pingping Li. Galectin-3 in metabolic disorders: mechanisms and therapeutic potential. Trends in Molecular Medicine 2025; 31(5) doi: 10.1016/j.molmed.2024.11.006
|
| 9 |
Zijian Sun, Binxia Chang, Miaomiao Gao, Jiyuan Zhang, Zhengsheng Zou. IL-33-ST2 Axis in Liver Disease: Progression and Challenge. Mediators of Inflammation 2017; 2017 doi: 10.1155/2017/5314213
|
| 10 |
Theodora Oikonomou, Ioannis Goulis, Fani Ntogramatzi, Zoi Athanasiadou, Eleni Vagdatli, Evangelos Akriviadis, Evangelos Cholongitas. Galectin-3 is associated with glomerular filtration rate and outcome in patients with stable decompensated cirrhosis. Digestive and Liver Disease 2019; 51(12) doi: 10.1016/j.dld.2019.05.030
|
| 11 |
Tea Lund Laursen, Anders Mellemkjær, Holger Jon Møller, Henning Grønbæk, Konstantin Kazankov. Spotlight on liver macrophages for halting injury and progression in nonalcoholic fatty liver disease. Expert Opinion on Therapeutic Targets 2022; 26(8) doi: 10.1080/14728222.2022.2132145
|
| 12 |
Mohammadjavad Sotoudeheian. Galectin-3 and Severity of Liver Fibrosis in Metabolic
Dysfunction-Associated Fatty Liver Disease. Protein & Peptide Letters 2024; 31(4) doi: 10.2174/0109298665301698240404061300
|
| 13 |
Ilias D. Vachliotis, Stergios A. Polyzos. The Intriguing Roles of Cytokines in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review. Current Obesity Reports 2025; 14(1) doi: 10.1007/s13679-025-00657-5
|
| 14 |
Atef Al Attar, Ani Antaramian, Mazen Noureddin. Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis. Expert Review of Clinical Pharmacology 2021; 14(4) doi: 10.1080/17512433.2021.1894127
|
| 15 |
Kristiaan Wouters, Alessia S. Cento, Katrien H. Gaens, Margee Teunissen, Jean L. J. M. Scheijen, Federica Barutta, Fausto Chiazza, Debora Collotta, Manuela Aragno, Gabriella Gruden, Massimo Collino, Casper G. Schalkwijk, Raffaella Mastrocola. Deletion of RAGE fails to prevent hepatosteatosis in obese mice due to impairment of other AGEs receptors and detoxifying systems. Scientific Reports 2021; 11(1) doi: 10.1038/s41598-021-96859-7
|
| 16 |
Mei-Juan Sun, Zhan-Qi Cao, Ping Leng. The roles of galectins in hepatic diseases. Journal of Molecular Histology 2020; 51(5) doi: 10.1007/s10735-020-09898-1
|
| 17 |
Xuebi Wu, Yongxin Ma, Xueshi Yin, Jianping Liu, Yongheng Zhang. Metabolic dysfunction–associated steatotic liver disease and heart failure with preserved ejection fraction: mechanisms and clinical implications from a heart–liver metabolic axis perspective. Frontiers in Pharmacology 2026; 17 doi: 10.3389/fphar.2026.1863710
|
| 18 |
Elke Roeb. Interleukin-13 (IL-13)—A Pleiotropic Cytokine Involved in Wound Healing and Fibrosis. International Journal of Molecular Sciences 2023; 24(16) doi: 10.3390/ijms241612884
|
| 19 |
Sanjana Nagraj, Spyros Peppas, Maria Gabriela Rubianes Guerrero, Damianos G Kokkinidis, Felipe I Contreras-Yametti, Sandhya Murthy, Ulrich P Jorde. Cardiac risk stratification of the liver transplant candidate: A comprehensive review. World Journal of Transplantation 2022; 12(7): 142-156 doi: 10.5500/wjt.v12.i7.142
|
| 20 |
Ke Pei, Ting Gui, Dongfang Kan, Huichao Feng, Yanqiang Jin, Ying Yang, Qian Zhang, Ziwei Du, Zhibo Gai, Jibiao Wu, Yunlun Li, Kusum Kharbanda. An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease. BioMed Research International 2020; 2020(1) doi: 10.1155/2020/4020249
|
| 21 |
Alison C. Mackinnon, Dimitar Tonev, Brian Jacoby, Massimo Pinzani, Robert J. Slack. Galectin-3: therapeutic targeting in liver disease. Expert Opinion on Therapeutic Targets 2023; 27(9) doi: 10.1080/14728222.2023.2258280
|
| 22 |
Nami Lee, Yu Jung Heo, Sung-E Choi, Ja Young Jeon, Seung Jin Han, Dae Jung Kim, Yup Kang, Kwan Woo Lee, Hae Jin Kim. Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease. Biochemical and Biophysical Research Communications 2022; 588 doi: 10.1016/j.bbrc.2021.12.065
|
| 23 |
Melisa Kozaczek, Walter Bottje, Byungwhi Kong, Diyana Albataineh, Reza Hakkak. A Comparison of Short- and Long-Term Soy Protein Isolate Intake and Its Ability to Reduce Liver Steatosis in Obese Zucker Rats Through Modifications of Genes Involved in Inflammation and Lipid Transport. Journal of Medicinal Food 2021; 24(9) doi: 10.1089/jmf.2020.0180
|
| 24 |
Devaraj Ezhilarasan. Unraveling the pathophysiologic role of galectin‐3 in chronically injured liver. Journal of Cellular Physiology 2023; 238(4) doi: 10.1002/jcp.30956
|
| 25 |
Sandra Rayego‐Mateos, José Luis Morgado‐Pascual, Cristina García‐Caballero, Iolanda Lazaro, Aleix Sala‐Vila, Lucas Opazo‐Rios, Sebastian Mas‐Fontao, Jesús Egido, Marta Ruiz‐Ortega, Juan Antonio Moreno. Intravascular hemolysis triggers NAFLD characterized by a deregulation of lipid metabolism and lipophagy blockade. The Journal of Pathology 2023; 261(2) doi: 10.1002/path.6161
|
| 26 |
Wangyan Jiang, Zhelong Liu, Shaohua Liu, Tingting Du. Associations of advanced liver fibrosis with heart failure with preserved ejection fraction in type 2 diabetic patients according to obesity and metabolic goal achievement status. Frontiers in Endocrinology 2023; 14 doi: 10.3389/fendo.2023.1183075
|
| 27 |
Hui Han, Romain Desert, Sukanta Das, Zhuolun Song, Dipti Athavale, Xiaodong Ge, Natalia Nieto. Danger signals in liver injury and restoration of homeostasis. Journal of Hepatology 2020; 73(4) doi: 10.1016/j.jhep.2020.04.033
|
| 28 |
Manhal Izzy, Lisa B. VanWagner, Grace Lin, Mario Altieri, James Y. Findlay, Jae K. Oh, Kymberly D. Watt, Samuel S. Lee. Redefining Cirrhotic Cardiomyopathy for the Modern Era. Hepatology 2020; 71(1) doi: 10.1002/hep.30875
|
| 29 |
Marcos Casado, Javier Gómez-Ambrosi, Beatriz Ramírez, Sara Becerril, Amaia Rodríguez, Víctor Valentí, Rafael Moncada, Camilo Silva, Javier Escalada, Gema Frühbeck, Victoria Catalán. Dual and context-dependent role of the interleukin-33/soluble suppression of tumorigenicity 2 axis in obesity and adipose tissue inflammation. Molecular Medicine 2026; 32(1) doi: 10.1186/s10020-026-01454-z
|
| 30 |
Stefano Fiorucci, Michele Biagioli, Eleonora Distrutti. Future trends in the treatment of non-alcoholic steatohepatitis. Pharmacological Research 2018; 134 doi: 10.1016/j.phrs.2018.07.014
|
| 31 |
S. Zhu, Z. Wu, W. Wang, L. Wei, H. Zhou. A revisit of drugs and potential therapeutic targets against non-alcoholic fatty liver disease: learning from clinical trials. Journal of Endocrinological Investigation 2023; 47(4) doi: 10.1007/s40618-023-02216-y
|
| 32 |
Tieshan Teng, Shuai Qiu, Yiming Zhao, Siyuan Zhao, Dequan Sun, Lingzhu Hou, Yihang Li, Ke Zhou, Xixi Yu, Changyong Yang, Yanzhang Li. Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences 2022; 23(14) doi: 10.3390/ijms23147841
|
| 33 |
Roxana Mihaela Chiorescu, Alexandru Ruda, Romeo Chira, Georgiana Nagy, Adriana Bințințan, Ștefan Chiorescu, Mihaela Mocan. Association of NT-proBNP and sST2 with Diastolic Dysfunction in Cirrhotic Patients and Its Therapeutic Implications. International Journal of Molecular Sciences 2025; 27(1) doi: 10.3390/ijms27010261
|
| 34 |
Andrew M. F. Johnson, Shaocong Hou, Pingping Li. Inflammation and insulin resistance: New targets encourage new thinking. BioEssays 2017; 39(9) doi: 10.1002/bies.201700036
|
| 35 |
Teodora Radu, Speranta Iacob, Bogdan Dorobanţu, Liana Gheorghe. Current Approach to Heart Failure. 2025; doi: 10.1007/978-3-031-96562-3_26
|
| 36 |
Kosuke Kaji, Soichi Takeda, Satoshi Iwai, Norihisa Nishimura, Shinya Sato, Tadashi Namisaki, Takemi Akahane, Hitoshi Yoshiji. Imeglimin Halts Liver Damage by Improving Mitochondrial Dysfunction in a Nondiabetic Male Mouse Model of Metabolic Dysfunction-Associated Steatohepatitis. Antioxidants 2024; 13(11) doi: 10.3390/antiox13111415
|
| 37 |
Na Cui, Lijuan Jiang, Lingli Tang, Haoneng Tang. Dynamic regulation of IL-33 in the obesity pathogenesis: Spatiotemporal specificity and functional paradoxes. Diabetes Research and Clinical Practice 2025; 229 doi: 10.1016/j.diabres.2025.112455
|
| 38 |
Marina Boziki, Stergios A. Polyzos, Georgia Deretzi, Evangelos Kazakos, Panagiotis Katsinelos, Michael Doulberis, Georgios Kotronis, Evaggelia Giartza-Taxidou, Leonidas Laskaridis, Dimitri Tzivras, Elisabeth Vardaka, Constantinos Kountouras, Nikolaos Grigoriadis, Robert Thomann, Jannis Kountouras. A potential impact of Helicobacter pylori -related galectin-3 in neurodegeneration. Neurochemistry International 2018; 113 doi: 10.1016/j.neuint.2017.12.003
|
| 39 |
Flavio A. Cadegiani. Dietary Interventions in Liver Disease. 2019; doi: 10.1016/B978-0-12-814466-4.00004-5
|
| 40 |
Tammy R. Chaudoin, Stephen J. Bonasera. Mice lacking galectin-3 (Lgals3) function have decreased home cage movement. BMC Neuroscience 2018; 19(1) doi: 10.1186/s12868-018-0428-x
|
| 41 |
Romain Itier, Maeva Guillaume, Jean-Etienne Ricci, François Roubille, Nicolas Delarche, François Picard, Michel Galinier, Jérôme Roncalli. Non-Alcoholic Fatty Liver Disease and Heart Failure with Preserved Ejection Fraction: From Pathophysiology to Practical Issues. ESC Heart Failure 2021; 8(2) doi: 10.1002/ehf2.13222
|
| 42 |
Milica M. Borovcanin, Slavica M. Janicijevic, Ivan P. Jovanovic, Nevena Gajovic, Nebojsa N. Arsenijevic, Miodrag L. Lukic. IL-33/ST2 Pathway and Galectin-3 as a New Analytes in Pathogenesis and Cardiometabolic Risk Evaluation in Psychosis. Frontiers in Psychiatry 2018; 9 doi: 10.3389/fpsyt.2018.00271
|
| 43 |
Maria Gabriela Delgado, Jaume Bosch. HVPG Measurements as a Surrogate of Clinical Events in Cirrhosis: Experience from Clinical Trials. Current Hepatology Reports 2019; 18(2) doi: 10.1007/s11901-019-00461-5
|
| 44 |
R.J. Slack, R. Mills, A.C. Mackinnon. The therapeutic potential of galectin-3 inhibition in fibrotic disease. The International Journal of Biochemistry & Cell Biology 2021; 130 doi: 10.1016/j.biocel.2020.105881
|
| 45 |
Madeleine Gill, Anoop N. Koshy, Jeyamani Ramachandran, Geoffrey W. McCaughan, Avik Majumdar. Cirrhotic cardiomyopathy: pathophysiology, assessment, and implications for liver transplantation. Therapeutic Advances in Gastroenterology 2026; 19 doi: 10.1177/17562848261423358
|
| 46 |
Linh Pham, Leonardo Baiocchi, Lindsey Kennedy, Keisaku Sato, Vik Meadows, Fanyin Meng, Chiung‐Kuei Huang, Debjyoti Kundu, Tianhao Zhou, Lixian Chen, Gianfranco Alpini, Heather Francis. The interplay between mast cells, pineal gland, and circadian rhythm: Links between histamine, melatonin, and inflammatory mediators. Journal of Pineal Research 2021; 70(2) doi: 10.1111/jpi.12699
|
| 47 |
Pio Conti, Gianpaolo Ronconi, Spyridon K. Kritas, Alessandro Caraffa, Theoharis C. Theoharides. Activated Mast Cells Mediate Low-Grade Inflammation in Type 2 Diabetes: Interleukin-37 Could Be Beneficial. Canadian Journal of Diabetes 2018; 42(5) doi: 10.1016/j.jcjd.2018.01.008
|
| 48 |
Ivan Srejovic, Dragica Selakovic, Nemanja Jovicic, Vladimir Jakovljević, Miodrag L. Lukic, Gvozden Rosic. Galectin-3: Roles in Neurodevelopment, Neuroinflammation, and Behavior. Biomolecules 2020; 10(5) doi: 10.3390/biom10050798
|
| 49 |
Svitlana Demyanets, Christoph Kaun, Alexandra Kaider, Walter Speidl, Manfred Prager, Stanislav Oravec, Philipp Hohensinner, Johann Wojta, Gersina Rega-Kaun. The pro-inflammatory marker soluble suppression of tumorigenicity-2 (ST2) is reduced especially in diabetic morbidly obese patients undergoing bariatric surgery. Cardiovascular Diabetology 2020; 19(1) doi: 10.1186/s12933-020-01001-y
|
| 50 |
Michael Kram. Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis. World Journal of Hepatology 2023; 15(2): 201-207 doi: 10.4254/wjh.v15.i2.201
|
| 51 |
Akira Hara, Masayuki Niwa, Kei Noguchi, Tomohiro Kanayama, Ayumi Niwa, Mikiko Matsuo, Yuichiro Hatano, Hiroyuki Tomita. Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases. Biomolecules 2020; 10(3) doi: 10.3390/biom10030389
|
| 52 |
Chung Eun Lee. Effects of Intermittent Fasting on Splenic Galectin-3 Protein Expression in High-fat Diet-fed Mice. Anatomy & Biological Anthropology 2023; 36(4) doi: 10.11637/aba.2023.36.4.209
|
| 53 |
Katrin Neumann, Birgit Schiller, Gisa Tiegs. NLRP3 Inflammasome and IL-33: Novel Players in Sterile Liver Inflammation. International Journal of Molecular Sciences 2018; 19(9) doi: 10.3390/ijms19092732
|
| 54 |
家亮 范. Metabolic Dysfunction-Associated Fatty Liver Disease and Cardiovascular Disease: Pathophysiological Mechanisms. Advances in Clinical Medicine 2024; 14(03) doi: 10.12677/acm.2024.143861
|
| 55 |
Suping Qin, Dexu Sun, Jingjing Mu, Daifu Ma, Renxian Tang, Yuanlin Zheng. Purple sweet potato color improves hippocampal insulin resistance via down-regulating SOCS3 and galectin-3 in high-fat diet mice. Behavioural Brain Research 2019; 359 doi: 10.1016/j.bbr.2018.11.025
|
| 56 |
Zhi Wang, Kailei Du, Nake Jin, Biao Tang, Wenwu Zhang. Macrophage in liver Fibrosis: Identities and mechanisms. International Immunopharmacology 2023; 120 doi: 10.1016/j.intimp.2023.110357
|
| 57 |
Darrell Pilling, Tejas R. Karhadkar, Richard H. Gomer, Qinghua Sun. A CD209 ligand and a sialidase inhibitor differentially modulate adipose tissue and liver macrophage populations and steatosis in mice on the Methionine and Choline-Deficient (MCD) diet. PLOS ONE 2020; 15(12) doi: 10.1371/journal.pone.0244762
|
| 58 |
Małgorzata Kalisz, Anna Litwiniuk, Natalia Sławkowska, Dominika Stępień, Wojciech Bik. Immunometabolic Organ Crosstalk in Heart Failure with Preserved Ejection Fraction: The Role of Dietary Patterns in Obesity-Related Inflammation. Nutrients 2026; 18(11) doi: 10.3390/nu18111720
|